AbbVie (ABBV) announced that it is in-licensing exclusive global rights to develop and commercialize FG-M701, a next-generation TL1A antibody for the treatment of inflammatory bowel disease (IBD), from the Chinese biotech FutureGen Biopharmaceutical.IBD includes two conditions, Crohn's disease (CD) and ulcerative colitis (UC), both characterized by chronic inflammation in the gastrointestinal tract. FG-M701, a novel TL1A inhibitor, is in pre-clinical development. It has been developed by FutureGen leveragin ...

With the markets trading at all-time highs, it’s natural to want to protect your gains by turning to a more defensive strategy. As we’ve seen throughout history, when the markets go up, they tend to pull back to retest key averages and demand levels. Are we ready for a correction? Nobody knows for sure, but it doesn’t hurt to start defending your portfolio after a strong bull run.One way to do this is to buy defensive dividend stocks. These can add stability, reduce volatility and provide cash flow for futu ...

-   Global license agreement to focus on the development of FG-M701, a TL1A antibody, for the treatment of inflammatory bowel disease (IBD)NORTH CHICAGO, Ill. and BEIJING, June 13, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and FutureGen Biopharmaceutical (Beijing) Co., Ltd. today announced a license agreement to develop FG-M701, a next generation TL1A antibody for the treatment of IBD currently in preclinical development.FG-M701 is a fully human monoclonal antibody targeting TL1A, a clinically validated targ ...

AbbVie, Inc. (NYSE:ABBV) Goldman Sachs 45th Annual Global Healthcare Conference June 12, 2024 10:00 AM ET Company Participants Robert Michael - President & COO Jeffrey Stewart - EVP & Chief Commercial Officer Roopal Thakkar - SVP & Chief Medical Officer, Global Therapeutics Scott Reents - EVP & CFO Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani Welcome everybody. Glad that you can join us. My name is Chris Shibutani, member at the Goldman Sachs Healthcare Research team. We are ...

AbbVie, Inc. (NYSE:ABBV) Goldman Sachs 45th Annual Global Healthcare Conference June 12, 2024 10:00 AM ET Company Participants Robert Michael - President & COO Jeffrey Stewart - EVP & Chief Commercial Officer Roopal Thakkar - SVP & Chief Medical Officer, Global Therapeutics Scott Reents - EVP & CFO Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani Welcome everybody. Glad that you can join us. My name is Chris Shibutani, member at the Goldman Sachs Healthcare Research team. We are ...

When it comes to targeting discounted ideas in the equities sector, undervalued blue-chip stocks offer some of the most compelling prospects. First and foremost, blue chips earn the status through decades of business and earnings expansion. In other words, they’re predictable stalwarts that can be depended on in good times and bad.As an investor, understanding this point gives you a clear advantage. Usually, when you hear about a “cheap” security in the financial information sector, it’s tied to an exciting ...

EXTON, PA, June 12, 2024 (GLOBE NEWSWIRE) -- Despite being the second IL-23 inhibitor to enter the market, AbbVie’s Skyrizi (risankizumab) is expected to have a substantial impact on ulcerative colitis (UC) treatment. Spherix Global Insights recently conducted the Q2 2024 wave of its UC RealTime Dynamix™ study, assessing the perspectives of gastroenterologists (n=101) on pipeline agents in development for UC, including Skyrizi. While Eli Lilly’s Omvoh, another IL-23 inhibitor, was approved in late 2023, ov ...

For The Second Year, 20 Women Entrepreneurs Will Each Receive $25,000 In Funding, Plus Access to Mentorship and Community—Helping to Close the Confidence GapIRVINE, Calif., June 11, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV) revealed this year's 20 BOTOX® Cosmetic grant recipients. Each inspiring woman entrepreneur will receive a $25,000 grant, mentorship, and access to community through the BOTOX® Cosmetic grant program in partnership with IFundWomen. The winners were h ...

AbbVie (ABBV) ended the recent trading session at $170.46, demonstrating a +0.61% swing from the preceding day's closing price. This change outpaced the S&P 500's 0.26% gain on the day. At the same time, the Dow added 0.18%, and the tech-heavy Nasdaq gained 0.35%.The drugmaker's stock has climbed by 5.39% in the past month, exceeding the Medical sector's gain of 3.06% and the S&P 500's gain of 3.25%.The investment community will be paying close attention to the earnings performance of AbbVie in its upcoming ...

Company Overview - AbbVie announced positive topline results from the phase II PICCOLO study for Elahere, achieving an objective response rate (ORR) of 51.9% in patients with FRα-positive platinum-sensitive ovarian cancer [1] - The median duration of response (DOR) was reported at 8.25 months, but it was not confirmed if this met the study goal [1] - Elahere has received full FDA approval for treating FRα-positive, platinum-resistant ovarian cancer and is also approved in Europe [2] Drug Development and Pipeline - Elahere is being evaluated in multiple studies as both monotherapy and in combination with other drugs, aiming to expand its use in earlier lines of therapy [2] - AbbVie acquired ImmunoGen for $10.1 billion, adding Elahere and other promising antibody-drug conjugates (ADCs) to its oncology pipeline [2] - Other ADC candidates in AbbVie's pipeline include pivekimab sunirine and IMGN-151, which are in various stages of clinical trials [2] Industry Trends - The ADC market is gaining traction, with significant investments from major pharmaceutical companies like AstraZeneca, Merck, and Pfizer [3][6] - AstraZeneca's Enhertu has shown strong market uptake, generating approximately $339 million in alliance revenues in Q1 2024 [4] - Pfizer's acquisition of Seagen for $43 billion has added three ADCs to its portfolio, enhancing its presence in the ADC space [5] Market Performance - AbbVie's shares have increased by 8.8% over the year, compared to the industry's growth of 18.9% [2] - AbbVie currently holds a Zacks Rank 3 (Hold) [7]